import { Helmet } from 'react-helmet-async';
import { Link } from 'react-router-dom';
import Navbar from '@/components/Navbar';
import Footer from '@/components/Footer';
import { BreadcrumbNav } from '@/components/seo/BreadcrumbNav';
import { FAQSection } from '@/components/healthcare-research/FAQSection';
import { getStandaloneReportConfig } from '@/data/reportConversionConfig';
import {
  ReportConsultationBand,
  ReportContentWithAside,
  ReportMidPageCta,
  ReportReadingProgress,
} from '@/components/report-conversion';
import { ReportPremiumHero, ReportPremiumSection } from '@/components/report-premium';

const pageUrl = 'https://www.bionixus.com/gcc-pharmaceutical-market-research';
const REPORT_CONVERSION = getStandaloneReportConfig('/gcc-pharmaceutical-market-research');

/**
 * FAQs target the stuck GSC queries ranking positions 40–70:
 * "gcc drug repurposing market", "gcc generic injectables market",
 * "gcc biologics market", "saudi arabia precision medicine market".
 */
const FAQ_ITEMS = [
  {
    question: 'What is the size of the GCC biologics market in 2026?',
    answer:
      'The GCC biologics market is estimated at USD 4.8–5.4 billion in 2026, driven by Saudi Arabia (~55% of regional spend) and the UAE (~20%). Growth is concentrated in oncology, autoimmune, and diabetes biologics, with biosimilar penetration accelerating after SFDA and MOHAP pathways matured in 2024–2025.',
  },
  {
    question: 'How big is the GCC generic injectables market?',
    answer:
      'The GCC generic injectables market is approximately USD 1.6–1.9 billion in 2026, with Saudi Arabia and the UAE accounting for the majority of hospital-administered volume. Demand is shaped by NUPCO tendering in KSA, MOHAP listing in the UAE, and a growing focus on local manufacturing under Vision 2030.',
  },
  {
    question: 'What is the GCC drug repurposing market opportunity?',
    answer:
      'GCC drug repurposing is an emerging opportunity driven by oncology, rare disease, and metabolic indications. Saudi Arabia and the UAE both fund repurposing through R&D grants and public–private partnerships. BioNixus tracks repurposing pipelines, payer appetite, and physician adoption signals across the six GCC markets.',
  },
  {
    question: 'How is the Saudi Arabia precision medicine market evolving?',
    answer:
      'Saudi Arabia precision medicine is one of the fastest-growing GCC subsegments, with the Saudi Genome Program, Vision 2030 health pillar, and SFDA companion-diagnostic guidance driving adoption. Oncology, rare disease, and pharmacogenomics are the most active therapy areas, supported by King Faisal, King Abdulaziz Medical City, and major academic networks.',
  },
  {
    question: 'How does BioNixus support GCC pharmaceutical market research?',
    answer:
      'BioNixus runs primary physician and KOL research, quantitative tracker programs, market access and pricing studies, KOL mapping, and competitive intelligence across Saudi Arabia, the UAE, Kuwait, Qatar, Bahrain, and Oman. Programs are bilingual (Arabic/English), SFDA/MOHAP-aware, and aligned to launch, access, and growth decision windows.',
  },
  {
    question: 'Which GCC therapy areas drive the most pharma growth in 2026?',
    answer:
      'In 2026, the fastest-growing GCC therapy areas are oncology, diabetes and obesity (GLP-1 driven), rare disease, immunology, and cardiovascular. Saudi Arabia and the UAE concentrate the bulk of innovative-medicine spend, while Kuwait and Qatar prioritize tendered generic and hospital-administered portfolios.',
  },
];

const FAQ_SECTION_ID = 'gcc-pharma-research-faq';

const faqPageSchema = {
  '@context': 'https://schema.org',
  '@type': 'FAQPage',
  url: `${pageUrl}#${FAQ_SECTION_ID}`,
  mainEntity: FAQ_ITEMS.map((item) => ({
    '@type': 'Question',
    name: item.question,
    acceptedAnswer: { '@type': 'Answer', text: item.answer },
  })),
};

const breadcrumbSchema = {
  '@context': 'https://schema.org',
  '@type': 'BreadcrumbList',
  itemListElement: [
    { '@type': 'ListItem', position: 1, name: 'Home', item: 'https://www.bionixus.com/' },
    { '@type': 'ListItem', position: 2, name: 'GCC Pharmaceutical Market Research', item: pageUrl },
  ],
};

const articleSchema = {
  '@context': 'https://schema.org',
  '@type': 'Article',
  headline: 'GCC Pharmaceutical Market Research — Biologics, Generic Injectables & Precision Medicine 2026',
  description:
    'GCC pharmaceutical market research with biologics, generic injectables, drug repurposing, and Saudi Arabia precision medicine intelligence for launch, access, and growth decisions.',
  url: pageUrl,
  datePublished: '2025-09-01',
  dateModified: '2026-05-25',
  author: { '@type': 'Organization', '@id': 'https://www.bionixus.com/#organization', name: 'BioNixus' },
  publisher: { '@type': 'Organization', '@id': 'https://www.bionixus.com/#organization', name: 'BioNixus' },
};

export default function GccPharmaceuticalMarketResearch() {
  return (
    <div className="min-h-screen bg-background">
      <Helmet>
        <title>GCC Biologics Market & Generic Injectables Research 2026 | BioNixus</title>
        <meta
          name="description"
          content="GCC biologics market, generic injectables, drug repurposing & Saudi Arabia precision medicine—pharmaceutical market research across KSA, UAE, Kuwait, Qatar, Bahrain and Oman."
        />
        <link rel="canonical" href={pageUrl} />
        <meta
          property="og:title"
          content="GCC Pharmaceutical Market Research — Biologics, Injectables & Precision Medicine 2026"
        />
        <meta
          property="og:description"
          content="Decision-ready GCC pharma research: biologics, generic injectables, drug repurposing, and Saudi Arabia precision medicine intelligence."
        />
        <meta property="og:type" content="article" />
        <meta property="og:url" content={pageUrl} />
        <script type="application/ld+json">{JSON.stringify(articleSchema)}</script>
        <script type="application/ld+json">{JSON.stringify(breadcrumbSchema)}</script>
        <script type="application/ld+json">{JSON.stringify(faqPageSchema)}</script>
      </Helmet>
      <Navbar />
      <ReportReadingProgress progressId="report-rp-gcc-pharmaceutical-market-research" />
      <main>
        <div className="section-padding pt-24 pb-4">
          <div className="container-wide">
            <BreadcrumbNav
              items={[
                { name: 'Home', href: '/' },
                { name: 'GCC Pharmaceutical Market Research', href: '/gcc-pharmaceutical-market-research' },
              ]}
            />
          </div>
        </div>

        <ReportPremiumHero
          title="GCC Pharmaceutical Market Research — Biologics, Generic Injectables & Precision Medicine 2026"
          description={
            <>
              <p>
                GCC pharmaceutical market research for launch, access, and growth across Saudi Arabia, the UAE,
                Kuwait, Qatar, Bahrain, and Oman. This page covers the four sub-segments where the regional market is
                moving fastest in 2026: the <strong className="font-medium text-foreground">GCC biologics market</strong>
                , the <strong className="font-medium text-foreground">GCC generic injectables market</strong>,{' '}
                <strong className="font-medium text-foreground">GCC drug repurposing</strong>, and the{' '}
                <strong className="font-medium text-foreground">Saudi Arabia precision medicine market</strong>.
              </p>
              <p className="mt-4 text-sm text-muted-foreground">
                For open-access market sizing and hospital consumption intelligence, see the{' '}
                <Link to="/gcc-pharma-market-report-2026" className="text-primary font-medium hover:underline">
                  GCC pharmaceutical market report 2026
                </Link>
                . For country and therapy programmes, use the{' '}
                <Link to="/healthcare-market-research" className="text-primary font-medium hover:underline">
                  healthcare market research hub
                </Link>
                .
              </p>
            </>
          }
          config={REPORT_CONVERSION}
          marketSlug="gcc"
          countryName="GCC"
          stats={[
            { value: '$4.8–5.4B', label: 'GCC biologics market 2026' },
            { value: '$1.6–1.9B', label: 'Generic injectables 2026' },
            { value: '6 markets', label: 'GCC country coverage' },
          ]}
        />

        <ReportContentWithAside
          config={REPORT_CONVERSION}
          tocItems={[
            { href: '#priority-segments', label: 'Priority segments' },
            { href: '#research-approach', label: 'Research approach' },
            { href: '#related-resources', label: 'Related resources' },
            { href: `#${FAQ_SECTION_ID}`, label: 'FAQ' },
          ]}
        >
          <ReportPremiumSection id="priority-segments" title="Priority GCC pharma segments in 2026" variant="cream">
            <div className="grid md:grid-cols-2 gap-4">
              <article className="rounded-xl border border-border bg-card p-5">
                <h3 className="font-semibold text-foreground mb-2">GCC biologics & generic injectables market</h3>
                <p className="text-sm text-muted-foreground">
                  Saudi Arabia and the UAE concentrate most biologics and hospital injectables spend; tracker programmes
                  follow biosimilar penetration, NUPCO tenders, and MOHAP listing. For KSA specifics, combine this hub
                  with the{' '}
                  <Link
                    to="/biosimilar-market-entry-saudi-arabia"
                    className="text-primary font-semibold underline underline-offset-2 hover:no-underline"
                  >
                    biosimilar market entry Saudi Arabia playbook
                  </Link>
                  .
                </p>
              </article>
              <article className="rounded-xl border border-border bg-card p-5">
                <h3 className="font-semibold text-foreground mb-2">
                  Saudi Arabia precision medicine & GCC drug repurposing
                </h3>
                <p className="text-sm text-muted-foreground">
                  The Saudi Genome Program and SFDA companion-diagnostic guidance are unlocking precision-medicine
                  launches; regional drug-repurposing activity is rising in oncology and rare disease.
                </p>
              </article>
            </div>
          </ReportPremiumSection>

          <ReportPremiumSection
            id="research-approach"
            title="How GCC pharmaceutical market research differs from a generic regional study"
          >
            <div className="space-y-4 text-muted-foreground leading-relaxed max-w-4xl">
              <p>
                Gulf markets share Arabic language touchpoints and Gulf Cooperation Council coordination on several
                policy themes, but payer logic, hospital procurement, and retail pharmacy dynamics still diverge
                materially between Riyadh, Dubai, Doha, and Manama. Effective GCC pharmaceutical market research
                therefore sequences evidence by country, aligns instruments to bilingual respondent preferences, and
                respects authority-specific confidentiality norms for physicians and payers.
              </p>
              <p>
                BioNixus designs modules for launch sequencing, pricing and access narratives, patient support program
                adoption, and competitive switching in crowded therapeutic classes. Where Saudi Vision 2030 reforms
                accelerate localization expectations, research must connect SFDA registration pathways to hospital
                formulary behavior and retail activation. Where UAE free-zone models influence access, interviews must
                capture both DHA and MOHAP realities alongside private hospital networks.
              </p>
              <p>
                Quantitative programs typically combine representative physician samples with clear screening for
                prescribing volume and institution type. Qualitative work layers KOL, payer, and pharmacist perspectives
                to explain why quantitative signals move—or stall—after policy announcements. Reporting should translate
                those signals into account lists, messaging guardrails, and scenario planning for leadership committees
                rather than stopping at chart decks.
              </p>
            </div>
          </ReportPremiumSection>

          <ReportPremiumSection id="related-resources" title="Related BioNixus resources" variant="muted">
            <div className="flex flex-wrap gap-3">
              <Link
                to="/bionixus-market-research-middle-east"
                className="rounded-lg bg-primary px-4 py-2.5 text-sm font-semibold text-primary-foreground"
              >
                Middle East pharmaceutical market research
              </Link>
              <Link
                to="/gcc-pharma-market-report-2026"
                className="rounded-lg border border-border px-4 py-2.5 text-sm font-semibold text-foreground hover:bg-muted"
              >
                GCC pharma market report 2026
              </Link>
              <Link
                to="/patient-support-program-research-gcc"
                className="rounded-lg border border-border px-4 py-2.5 text-sm font-semibold text-foreground hover:bg-muted"
              >
                Patient support program research GCC
              </Link>
            </div>
            <ReportMidPageCta config={REPORT_CONVERSION} className="mt-8" />
          </ReportPremiumSection>

          <FAQSection
            sectionId={FAQ_SECTION_ID}
            title="GCC pharmaceutical market — biologics, injectables, precision medicine & drug repurposing FAQ"
            items={FAQ_ITEMS}
            className="bg-muted/30 rounded-2xl px-4 md:px-6"
          />
        </ReportContentWithAside>

        <ReportConsultationBand config={REPORT_CONVERSION} />
      </main>
      <Footer />
    </div>
  );
}
